Pharmacological study of piroheptine, a new antiparkinson drug, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-ethyl-2-methylpyrrolidine. I. Effects on drug-induced tremor and catatonia, and on adrenergic actions.
D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology; D001285:Atropine / Q000494:pharmacology; D001362:Avoidance Learning / Q000187:drug effects; D002389:Catatonia / Q000139:chemically induced / Q000188:drug therapy; D002415:Cats; D003213:Conditioning, Psychological / Q000187:drug effects; D000882:Haplorhini; D006801:Humans; D008251:Macaca; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009043:Motor Activity / Q000187:drug effects; D009541:Nictitating Membrane / Q000187:drug effects; D010276:Parasympatholytics / Q000494:pharmacology*; D011398:Promethazine / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D014202:Tremor / Q000139:chemically induced / Q000188:drug therapy; D014282:Trihexyphenidyl / Q000494:pharmacology
D000978:Antiparkinson Agents; D010276:Parasympatholytics; D011759:Pyrrolidines; D014282:Trihexyphenidyl; D001285:Atropine; D011398:Promethazine